Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Mar 6;4(2):e988098.
doi: 10.4161/21505594.2014.988098. eCollection 2015 Feb.

Oncolytic virus expressing RANTES and IL-15 enhances function of CAR-modified T cells in solid tumors

Nobuhiro Nishio  1 , Gianpietro Dotti  2
Affiliations
Review

Oncolytic virus expressing RANTES and IL-15 enhances function of CAR-modified T cells in solid tumors

Nobuhiro Nishio et al. Oncoimmunology. .

Abstract

We improved the migration and survival of chimeric antigen receptor (CAR)-modified T cells in solid tumors by combining CAR-T cells with an armed oncolytic virus. Local delivery of the chemokine RANTES and the cytokine IL-15 by the oncolytic virus enhanced the trafficking and persistence of the CAR-T cells, resulting in improved antitumor effects.

Keywords: GD2 antigen; IL-15; RANTES; chimeric antigen receptor; oncolytic virus.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Combined therapy with CAR-T cells and Ad5Δ24 armed with RANTES and IL-15. Oncolytic viruses (OVs) selectively infect and lyse tumor cells, and then spread to neighboring tumor cells. Virus-infected tumor cells release both proteins and undergo apoptosis. The chemokine RANTES attracts circulating chimeric antigen receptor (CAR) modified T cells (CAR-T) to the virus infected tumor site and migrated CAR-T cells persist by virtue of interleukin 15 (IL-15) and specific antigen stimulation.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, et al. . Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371:1507-17; PMID:; http://dx.doi.org/10.1056/NEJMoa1407222 - DOI - PMC - PubMed
    1. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, Kamble RT, Bollard CM, Gee AP, Mei Z, et al. . CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 2011; 121:1822-6; PMID:; http://dx.doi.org/10.1172/JCI46110 - DOI - PMC - PubMed
    1. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, et al. . CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013; 5:177ra38; PMID:; http://dx.doi.org/10.1126/scitranslmed.3005930 - DOI - PMC - PubMed
    1. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR, et al. . Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009; 114:535-46; PMID:; http://dx.doi.org/10.1182/blood-2009-03-211714 - DOI - PMC - PubMed
    1. Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev 2014; 257:107-26; PMID:; http://dx.doi.org/10.1111/imr.12131 - DOI - PMC - PubMed

Publication types